Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Fineline Cube Dec 18, 2025
Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Fineline Cube Dec 18, 2025
Company Deals

Shenzhen Würzburg Dynamics Raises RMB 100 Million in Series A Financing Round

Fineline Cube Dec 27, 2022

China-based Shenzhen Würzburg Dynamics has reportedly raised RMB 100 million (USD 14.36 million) in a...

Company Deals

AcornMed Raises RMB 200 Million in Series B Financing Led by Yikai Venture Capital

Fineline Cube Dec 27, 2022

AcornMed, a tumor precision medicine specialist based in Beijing, has reportedly raised RMB 200 million...

Company Drug

CSPC’s NBL-020 Receives FDA IND Approval for Advanced Solid Tumors

Fineline Cube Dec 26, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving Investigational New Drug (IND) approval...

Company Drug

Jiangsu Chia Tai Tianqing’s TQB2102m Gains NMPA Clinical Approval

Fineline Cube Dec 26, 2022

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd’s (CTTQ) Category 1 biologic product TQB2102m, an HER2...

Company Deals

WuXi XDC Partners with GeneQuantum for ADC Development

Fineline Cube Dec 26, 2022

China-based WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a...

Company Drug

Hengrui Pharmaceuticals Receives New Approval for Remimazolam Tosylate

Fineline Cube Dec 26, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced one new supplementary approval for its gamma-aminobutyric...

Company Deals

Neurophth Partners with Apellis for Gene Therapy Development in AMD

Fineline Cube Dec 26, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with US firm...

Company Drug

Jing Medicine’s HJM-353 Gains Clinical Trial Approvals in US and China

Fineline Cube Dec 26, 2022

China-based Jing Medicine Technology (Shanghai) Co., Ltd’s HJM-353 has obtained clinical trial approvals in the...

Company Deals

Jiangsu Vcare PharmaTech Raises RMB 200 Million in Series B Financing Round

Fineline Cube Dec 26, 2022

China-based Jiangsu Vcare PharmaTech Co. Ltd has reportedly raised over RMB 200 million (USD 28.67...

Company Drug

MindRank AI Receives FDA Approval for MDR-001 Clinical Study in Obesity

Fineline Cube Dec 26, 2022

Hangzhou-based artificial intelligence (AI)-driven biotech MindRank AI has announced obtaining approval from the US FDA...

Company Medical Device

Hangzhou Biotest Receives FDA EUA for COVID-19 Antigen Self-Testing Reagent

Fineline Cube Dec 26, 2022

China-based Hangzhou Biotest Biotech Co., Ltd has announced receiving an Emergency Use Authorization (EUA) from...

Company Deals

Junshi Biosciences Licenses PD-1 Inhibitor Tuoyi to Hikma MENA FZE

Fineline Cube Dec 26, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a licensing agreement with UK-headquartered Hikma...

Company Deals

Shanghai Pharmaceuticals Secures Exclusive Rights for Shionogi’s Ensitrelvir in China

Fineline Cube Dec 26, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced an import and distribution agreement with Japan-based...

Company Drug

WHO Approves Sinovac’s CoronaVac for Children Aged 3 and Above

Fineline Cube Dec 23, 2022

The World Health Organization (WHO) has lowered the age limit for Sinovac Biotech Ltd’s (NASDAQ:...

Policy / Regulatory

NHSA Orders Investigation into Unreasonable Medical Insurance Restrictions

Fineline Cube Dec 23, 2022

The National Healthcare Security Administration (NHSA) has released a notification to medical insurance departments across...

Company Drug

Fosun Pharma’s Avatrombopag Receives NMPA Review for Chronic ITP Indication

Fineline Cube Dec 23, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that another...

Company Deals

Nanjing Pharmaceutical to Acquire Majority Stakes in Three Jiangsu Subsidiaries

Fineline Cube Dec 23, 2022

China-based Shanghai-listed Nanjing Pharmaceutical Co., Ltd (SHA: 600713) is set to acquire a respective 55%,...

Company Deals

MSD and Kelun Biotech Ink Record-Breaking ADC Deal

Fineline Cube Dec 23, 2022

Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest...

Policy / Regulatory

NMPA and GAC Release Notification on Import and Export Management of Narcotic Drugs

Fineline Cube Dec 23, 2022

The National Medical Products Administration (NMPA) and the General Administration of Customs (GAC) have released...

Company Drug

Shyndec’s Generic Cytosar-U Gains Marketing Approval in China

Fineline Cube Dec 23, 2022

China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of...

Posts pagination

1 … 516 517 518 … 599

Recent updates

  • Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
  • DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer
  • Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan
  • Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets
  • Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Company Drug

Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan

Company Drug

Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.